BE554362A - Process for manufacturing a physiological dietetic product for newborns and infants - Google Patents
Process for manufacturing a physiological dietetic product for newborns and infantsInfo
- Publication number
- BE554362A BE554362A BE554362A BE554362A BE554362A BE 554362 A BE554362 A BE 554362A BE 554362 A BE554362 A BE 554362A BE 554362 A BE554362 A BE 554362A BE 554362 A BE554362 A BE 554362A
- Authority
- BE
- Belgium
- Prior art keywords
- proteins
- immunizing
- process according
- inhibitor
- globulins
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 21
- 235000005911 diet Nutrition 0.000 title claims description 3
- 230000000378 dietary effect Effects 0.000 title claims description 3
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 230000003053 immunization Effects 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 108010044091 Globulins Proteins 0.000 claims description 5
- 102000006395 Globulins Human genes 0.000 claims description 5
- 230000001475 anti-trypsic effect Effects 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 108010074605 gamma-Globulins Proteins 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000000636 anti-proteolytic effect Effects 0.000 claims description 3
- 235000021277 colostrum Nutrition 0.000 claims description 3
- 210000003022 colostrum Anatomy 0.000 claims description 3
- 230000003169 placental effect Effects 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 108010005642 Properdin Proteins 0.000 claims description 2
- 102100038567 Properdin Human genes 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 235000015278 beef Nutrition 0.000 claims description 2
- 210000000941 bile Anatomy 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 235000015277 pork Nutrition 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims 2
- 108010087504 Beta-Globulins Proteins 0.000 claims 1
- 102000006734 Beta-Globulins Human genes 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 230000001502 supplementing effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 description 3
- 229940124452 immunizing agent Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000035404 Autolysis Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
- A23C9/206—Colostrum; Human milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
<Desc/Clms Page number 1>
La présente invention a.pour objet un procédé de fabrication d'un produit diététique pour nouveaux-nés et nourrissons..
<Desc/Clms Page number 2>
Ce procédé est caractérisé par le fait qu'on incorpore des protides immunisants à un support à base de constituants du lait susceptible de faciliter le transfert dans le sang du.nourrisson de ces protides ingérés per os.
On a toujours considéré que le transfert dans le sang de protides ingérés per os n'était pas possible, aussi n'a-t-on, jusqu'à présent, pas tenté de les incor- 'porer à des aliments pour nouveaux-nés et nourrissons à titre d'agents immunisants contre les maladies de la prime enfance. Or, de récents travaux ont montré que, contrairement aux'notions communément admises, ce passage dans le sang de protides ingérés per os se produisait effectivement. Cependant, pour être efficace, ce passage doit être favorisé par un support adéquat.
Le but de la présente invention est de permettre l'obtention d'un produit pour nouveaux-nés, ingérable per os, qui comprenne à la fois les anticorps immunisants et le support à base de constituants du lait facilitant leur transfert dans le sang.
Les protides immunisants utilisés pourront être soit aspécifiques, soit au contraire spécifiques des maladies dont on désire protéger le nourrisson. Ces protides pourront être des protéines, notamment des gamma et beta 1 globulines. Celles-ci seront soit hétérologues, soit homologues d'origine sérique, placentaire ou mammaire. Elles seront prélevées de préférence sur des sujets humains ou animaux hyperimmunisés contre les maladies spécifiques de la prime enfance, mais on pourrait aussi les prélever
<Desc/Clms Page number 3>
sur des sujets standard naturellement immunisés.
Les gamma globulines placentaires présentent l'avantage de provenir d'une source moins coûteuse que les gamma globulines sériques, d'autant plus qu'étant destinées à être ingérées par voie buccale, il n'est pas nécessaire de les purifier comme ce serait le cas si elles devaient être administrées par injection (absence d'hémoglobine, de substances pyrogènes, par exemple).. Les globulines d'origine mammaire constituent la source la plus naturelle et dans certaines conditions la plus abondante de protéines immunisantes.
Au lieu de gamma globulines, on pourrait utiliser, comme protide immunisant, de la properdine ou une autre substance protectrice non spécifique. On pourrait également envisager l'emploi d'antigènes conférant une immunisation active spécifique, tels que microbes et vi- rus tués ou atténués par voie chimique, physique ou biologique, ou fragments protéiques de ces microorganismes ayant conservé l'activité antigénique.
On pourra prévoir un agent'complétant l'action du support facilitant le transfert dans le sang des protides immunisants.administrés per os; cet agent, ajouté au support à base de constituants du lait ou du colostrum, pourra contenir, lorsque les agents 'immunisants sont des protéines, un inhibiteur de la digestion de ces protéines; cet inhibiteur, agissant par exemple sur les enzymes protéolytiques du tractus digestif, pourra être un inhibiteur antitrypsique extrait de colostrum animal. On choisira alors de 'préférence le porc ou le boeuf. Cet inhibiteur
<Desc/Clms Page number 4>
pourrait être d'origine végétale tel que le facteur anti- trypsique de la graine de soja.
Enfin, on pourrait utili- ser, comme inhibiteur antiprotéolytique, des polypeptides résultant d'autolyses tissulaires par l'enzyme considéré ou des polypeptides synthétiques tels que l'acide poly- glutamique pour l'inhibition de la trypsine ou la polyly- sine pour l'inhibition de la pepsine.
Le transfert dans le sang des protides immu- nisants pourrait aussi être facilité en favorisant la ré- sorption 'de ces protides au niveau de la surface intesti- nale ; le ,rôle du support pourrait alors être complété par l'addition de bile ou de ses dérivés.
<Desc / Clms Page number 1>
The present invention relates to a method of manufacturing a dietetic product for newborns and infants.
<Desc / Clms Page number 2>
This process is characterized by the fact that immunizing proteins are incorporated in a support based on milk constituents capable of facilitating the transfer into the blood of the infant of these proteins ingested per os.
It has always been considered that the transfer into the blood of proteins ingested per os was not possible, so no attempt has been made to incorporate them into foods for newborns until now. and infants as immunizing agents against diseases of early childhood. However, recent work has shown that, contrary to commonly accepted emotions, this passage into the blood of proteins ingested per os does indeed occur. However, to be effective, this passage must be favored by an adequate support.
The aim of the present invention is to make it possible to obtain a product for newborns, ingestible per os, which comprises both the immunizing antibodies and the support based on constituents of milk facilitating their transfer into the blood.
The immunizing proteins used may be either non-specific or, on the contrary, specific to the diseases from which it is desired to protect the infant. These proteins may be proteins, in particular gamma and beta 1 globulins. These will be either heterologous or homologous of serum, placental or mammary origin. They will preferably be taken from human subjects or animals hyperimmunized against specific diseases of early childhood, but we could also take them
<Desc / Clms Page number 3>
on naturally immune standard subjects.
Placental gamma globulins have the advantage of coming from a less expensive source than serum gamma globulins, especially since being intended to be ingested orally, it is not necessary to purify them as would be the case. If they had to be administered by injection (absence of hemoglobin, pyrogenic substances, for example). Globulins of mammary origin constitute the most natural source and under certain conditions the most abundant of immunizing proteins.
Instead of gamma globulins, properdin or other non-specific protective substance could be used as the immunizing protein. It would also be possible to envisage the use of antigens conferring a specific active immunization, such as microbes and viruses killed or attenuated by chemical, physical or biological means, or protein fragments of these microorganisms which have retained the antigenic activity.
It is possible to provide an agent complementing the action of the carrier facilitating the transfer into the blood of the immunizing proteins. Administered per os; this agent, added to the support based on constituents of milk or colostrum, may contain, when the immunizing agents are proteins, an inhibitor of the digestion of these proteins; this inhibitor, acting for example on the proteolytic enzymes of the digestive tract, could be an antitrypsic inhibitor extracted from animal colostrum. Pork or beef will then be chosen preferably. This inhibitor
<Desc / Clms Page number 4>
could be of plant origin such as anti-tryptic factor in soybeans.
Finally, one could use, as antiproteolytic inhibitor, polypeptides resulting from tissue autolysis by the enzyme considered or synthetic polypeptides such as polyglutamic acid for the inhibition of trypsin or polylysin for l. pepsin inhibition.
The transfer of immunizing proteins into the blood could also be facilitated by promoting the absorption of these proteins at the level of the intestinal surface; the role of the support could then be completed by the addition of bile or its derivatives.
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU34137A LU34137A1 (en) | 1956-01-25 | 1956-01-25 | Process for the manufacture of a physiological dietary product for newborns and infants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE554362A true BE554362A (en) | 1957-02-15 |
Family
ID=1768426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE554362A BE554362A (en) | 1956-01-25 | 1957-01-21 | Process for manufacturing a physiological dietetic product for newborns and infants |
Country Status (3)
| Country | Link |
|---|---|
| BE (1) | BE554362A (en) |
| FR (1) | FR1164897A (en) |
| LU (1) | LU34137A1 (en) |
-
1956
- 1956-01-25 LU LU34137A patent/LU34137A1/en unknown
-
1957
- 1957-01-21 BE BE554362A patent/BE554362A/en unknown
- 1957-01-21 FR FR1164897D patent/FR1164897A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR1164897A (en) | 1958-10-15 |
| LU34137A1 (en) | 1957-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reilly et al. | Oral delivery of antibodies: future pharmacokinetic trends | |
| Lloyd et al. | The role of IgA immunoglobulins in the passive transfer of protection to Taenia taeniaeformis in the mouse. | |
| US9409996B2 (en) | Treatment of food intolerance and food allergy with IgM | |
| JP3195631B2 (en) | Method for producing specific chicken egg antibody | |
| US5753228A (en) | Method of treating parasitosis by the enteral administration of hyperimmune hen egg yolk antibodies | |
| FI98269C (en) | Method for isolating a substantially pure, anti-inflammatory factor from milk | |
| Allen et al. | Localization by immunofluorescence of secretory component and IgA in the intestinal mucosa of the young pig | |
| US4344938A (en) | Agent for the treatment of allergic reactions | |
| Bazin | The secretory antibody system | |
| US5814345A (en) | Immune suppressive product | |
| Telemo et al. | Proteolytic activity as a regulator of the transmission of orally fed proteins from the gut to the blood serum in the suckling rat | |
| AU648800B2 (en) | Immune suppressive product | |
| US5951984A (en) | Method for inducing immunological tolerance, immunological tolerance inducing food kit, and immunological tolerance inducer kit | |
| BE554362A (en) | Process for manufacturing a physiological dietetic product for newborns and infants | |
| JP5272115B2 (en) | Peptide composition for inducing oral immune tolerance and method for producing the same | |
| EP1589995B1 (en) | Use of avian antibodies | |
| Jost et al. | Reduction of whey protein allergenicity by processing | |
| US6054124A (en) | Immune suppressive product | |
| RU2180573C2 (en) | Method to prevent dyspepsia and correct immune homeostasis in neonatal calves | |
| JPS59184133A (en) | Preparation of igm | |
| EP0722952B1 (en) | Hypoallergenic serocolostral fraction having high antibody activity, use and process for preparing such a fraction | |
| RU93056598A (en) | PRODUCTS CONTAINING ACTIVE MILK PROTEIN COMPONENTS AND METHODS OF THEIR RECEIVING | |
| Murray et al. | The ecological interdependence of diet and disease in tribal societies. | |
| Grabar | The “globulines-transporteurs” theory and auto-sensitization | |
| JP5598504B2 (en) | Peptide composition for inducing oral immune tolerance and method for producing the same |